Pralnacasan (vertex pharmaceuticals)

IDrugs. 2003 Feb;6(2):154-8.

Abstract

Vertex is collaborating with Aventis Pharma AG (formerly Hoechst Marion Roussel Inc) in the development of pralnacasan, an interleukin (IL)-1b converting enzyme (ICE) inhibitor, for the potential treatment of inflammatory diseases [170247], [188293], [453094].

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal* / chemistry
  • Anti-Inflammatory Agents, Non-Steroidal* / pharmacology
  • Anti-Inflammatory Agents, Non-Steroidal* / therapeutic use
  • Azepines* / chemistry
  • Azepines* / pharmacology
  • Azepines* / therapeutic use
  • Caspase Inhibitors
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Humans
  • Isoquinolines* / chemistry
  • Isoquinolines* / pharmacology
  • Isoquinolines* / therapeutic use
  • Protease Inhibitors* / chemistry
  • Protease Inhibitors* / pharmacology
  • Protease Inhibitors* / therapeutic use
  • Pyridazines* / chemistry
  • Pyridazines* / pharmacology
  • Pyridazines* / therapeutic use
  • Structure-Activity Relationship
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Azepines
  • Caspase Inhibitors
  • Isoquinolines
  • Protease Inhibitors
  • Pyridazines
  • pralnacasan